Latest Breaking News On - Dermtech melanoma test - Page 2 : comparemela.com

San Diego biotech company making melanoma skin test patch cuts 56% of its workforce

San Diego-based DermTech is also exploring the possibility of a merger, acquisition, sale of assets, licensing or other transaction.

San-diego
California
United-states
Drug-administration
Veterans-affairs
Nasdaq
Exchange-commission
San-diego-based
Dermtech-smart-sticker
Dermtech-melanoma-test

DermTech (DMTK) to Explore Strategic Alternatives and Implement Restructuring Plan

DermTech (DMTK) to Explore Strategic Alternatives and Implement Restructuring Plan
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Nasdaq
Dermtech-inc
Dermtech-melanoma-test

DermTech Reports Fourth-Quarter 2023 Financial Results

DermTech Reports Fourth-Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Steve-kunszabo
Bret-christensen
Company-form
Nasdaq
Dermtech-inc
Exchange-commission
Dermtech-melanoma-test
Private-securities-litigation-reform-act
Annual-report
Months-ended-december
Balance-sheets

DermTech (DMTK) to Release Quarterly Earnings on Thursday

DermTech (NASDAQ:DMTK – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, February 29th. Analysts expect DermTech to post earnings of ($0.54) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link. DermTech Stock […]

Switzerland
United-states
Swiss
Dermtech-company-profile
Dermtech-inc
Swiss-national-bank
Centaurus-financial-inc
Jpmorgan-chase-co
Charles-schwab-investment-management-inc
Get-free-report
Schwab-investment-management

DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations

- Ongoing emphasis on growing revenue for the DermTech Melanoma Test - Approximately $40 million in total operating expense reductions compared to fiscal 2022 resulting from all restructuring.

Bret-christensen
Nasdaq
Dermtech-inc
Dermtech-melanoma-test
Markets